Product Description
ANB032 silences pro-inflammatory signaling by modulating BTLA binding to HVEM.
Mechanisms of Action: BTLA Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AnaptysBio
Company Location: Western America
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Czech Republic, Poland
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - AnaptysBio announced they will present P2 Dermatitis, Atopic results in 4Q24 for ANB-032
- Clinical Outcomes Reported - AnaptysBio announced they will present P2 Dermatitis|Dermatitis, Atopic results in YE24 for ANB-032
- Clinical Outcomes Reported - AnaptysBio announced they will present P2 Dermatitis, Atopic results in YE24 for ANB-032
Highest Development Phases
Phase 2: Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-503522-40-01 |
ANB032-201 | P2 |
Completed |
Dermatitis, Atopic |
2024-12-11 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/05/2024 |
News Article |
Anaptys Announces Participation in November and December Investor Conferences |
|
08/29/2024 |
News Article |
Anaptys Announces Participation in September Investor Conferences |
|
08/14/2024 |
News Article |
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering |
|
05/09/2024 |
News Article |
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) |